Smoldering Multiple Myeloma
- 28 December 2023
- journal article
- research article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 38 (2) , 293-303
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (CA 168762, CA186781)
- National Cancer Institute
This publication has 36 references indexed in Scilit:
- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaLeukemia, 2013
- High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myelomaLeukemia, 2012
- Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized studyLeukemia & Lymphoma, 2011
- Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort studyThe Lancet, 2010
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementLeukemia, 2010
- Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple MyelomaJournal of Clinical Oncology, 2010
- A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myelomaCancer, 2008
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaBlood, 2008
- Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple MyelomaNew England Journal of Medicine, 2007
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2002